Smith Nicholas Conrad, the President and CFO of Alto Neuroscience, Inc., has recently executed a series of stock transactions that may have implications for the company and its stakeholders. The transactions, filed on October 1, 2026, involve both acquisitions and disposals of shares, showcasing an active management approach to equity ownership.
Alto Neuroscience, Inc. operates in the pharmaceutical preparations sector, focusing on innovative solutions in mental health and neuroscience. The company is incorporated in Delaware and has a fiscal year ending on December 31. It trades under the ticker symbol ANRO and is recognized for its commitment to advancing therapeutic options in the life sciences domain.
According to the filing, Conrad engaged in multiple transactions on September 29 and 30, 2026. Notably, he acquired a total of 56,455 shares and 54,375 shares at a price of $2.35 per share. He also disposed of 110,830 shares at a price of approximately $26.58 per share, which significantly impacts his overall ownership stake in the company. Following these transactions, he retains ownership of 24,060 shares.
The filing indicates that these transactions are part of a Rule 10b5-1 trading plan adopted by Conrad on June 30, 2026. This plan allows executives to sell shares at predetermined times, helping to avoid any potential insider trading allegations. Such plans are common among executives to manage their stock holdings transparently.
These stock transactions may affect various stakeholders, including investors, employees, and analysts observing Alto Neuroscience's performance. The fluctuations in ownership and the strategic decisions behind these trades can influence investor confidence and market perceptions of the company's direction.
Looking ahead, the filing does not specify any forthcoming actions or additional filings related to these transactions. However, the ongoing management of stock ownership by executives like Conrad is expected to continue shaping the corporate governance landscape at Alto Neuroscience.